Key points are not available for this paper at this time.
Assess whether 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDp/CDp) improves Parkinson's Disease Sleep Scale-2 (PDSS-2) subdomains in people with Parkinson's (PwP).
Hauser et al. (Tue,) studied this question.